We are a fully-integrated pharmaceutical company that develops, manufactures and markets injectable pharmaceutical products. We believe that we are the only independent U.S. public company with a primary focus on the injectable critical care, anti-infective and oncology markets, and we further believe that we offer one of the most comprehensive injectable product portfolios in the pharmaceutical industry. We manufacture products in each of the three basic forms in which injectable products are sold: liquid, powder and lyophilized, or freeze-dried. Our products are generally used in hospitals, long-term care facilities, alternate care sites and clinics within North America. Unlike the retail pharmacy market for oral products, the injectable pharmaceuticals marketplace is largely made up of end users who have relationships with group purchasing organizations, or GPOs, and/or specialty distributors who distribute products within a particular end-user market, such as oncology clinics. GPOs and specialty distributors generally enter into collective product purchasing agreements with pharmaceutical suppliers in an effort to secure more favorable drug pricing on behalf of their members.
Company profile
Ticker
ABBI
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Abraxis BioScience, Inc., Abraxis BioScience, Inc. , American Pharmaceutical Partners Inc, American Pharmaceutical Partners Inc
SEC CIK
Corporate docs
IRS number
680389419
Latest filings (excl ownership)
POSASR
Automatic shelf registration (post-effective amendment)
30 Sep 08
S-8 POS
Registration of securities for employees (post-effective amendment)
30 Sep 08
S-8 POS
Registration of securities for employees (post-effective amendment)
30 Sep 08
S-8 POS
Registration of securities for employees (post-effective amendment)
30 Sep 08
S-8 POS
Registration of securities for employees (post-effective amendment)
30 Sep 08
S-8 POS
Registration of securities for employees (post-effective amendment)
30 Sep 08
15-12G
Securities registration termination
22 Sep 08
8-K
Changes in Control of Registrant
16 Sep 08
25-NSE
Exchange delisting
10 Sep 08
425
Business combination disclosure
10 Sep 08
Latest ownership filings
11-K
Annual report of employee stock purchases
30 Jun 08
11-K
Annual report of employee stock purchases
13 Jul 07
NT 11-K
Notice of inability to timely file Form 11-K
29 Jun 07
11-K
Annual report of employee stock purchases
28 Jun 06
11-K
Annual report of employee stock purchases
29 Jun 05
11-K
Annual report of employee stock purchases
25 Jun 04
11-K
Annual report of employee stock purchases
30 Jun 03